Cargando…

COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits

Detalles Bibliográficos
Autores principales:	Vuk, T., Hećimović, A., Jukić, I., Ravlić, S., Kurtović, T., Rnjak, D., Halassy, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205291/ https://www.ncbi.nlm.nih.gov/pubmed/34172379 http://dx.doi.org/10.1016/j.tracli.2021.06.001

Ejemplares similares

COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
por: Rnjak, D., et al.
Publicado: (2021)

COVID-19 convalescent plasma therapy and immunodeficiency
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Efficient and Sustainable Platform for Preparation of a High-Quality Immunoglobulin G as an Urgent Treatment Option During Emerging Virus Outbreaks
por: Kurtović, Tihana, et al.
Publicado: (2022)

Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?
por: Ravlić, Sanda, et al.
Publicado: (2022)

Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?
por: Basic-Jukic, Nikolina
Publicado: (2020)

The true historical origin of convalescent plasma therapy
por: Marson, Piero, et al.
Publicado: (2020)

Convalescent plasma (CP) therapy in patients with COVID-19
por: Cakir, Banu
Publicado: (2021)

Risk–benefit analysis on the clinical significance of convalescent plasma therapy in the management of COVID-19
por: Dhanasekaran, Sivaraman, et al.
Publicado: (2020)

Convalescent plasma therapy for persistent hepatitis E virus infection
por: Ankcorn, Michael, et al.
Publicado: (2019)

Convalescent plasma for COVID-19 considerations
por: Adiwinata Pawitan, Jeanne
Publicado: (2021)

COVID-19 Pandemic and the Convalescent Plasma Therapy: Possible Benefits and Risks
por: Noor, Rashed, et al.
Publicado: (2021)

Blood donation during natural disasters – experience with COVID-19 and earthquakes in Croatia
por: Jukić, Irena, et al.
Publicado: (2021)

Convalescent plasma in the management of COVID-19 pneumonia
por: Elbadawi, Ayman, et al.
Publicado: (2021)

How Safe Is COVID-19 Convalescent Plasma?
por: Franchini, Massimo, et al.
Publicado: (2021)

Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
por: London, Jonathan, et al.
Publicado: (2020)

‘Treatment of COVID-19 with convalescent plasma’ – Author’s reply
por: Wooding, Denise J., et al.
Publicado: (2021)

Use of convalescent plasma in COVID-19 patients in China
por: Zhu, M., et al.
Publicado: (2020)

In Reply—How Safe Is COVID-19 Convalescent Plasma?
por: Joyner, Michael J., et al.
Publicado: (2021)

Convalescent plasma therapy in COVID 19: Every dark cloud has a silver lining
por: Deokar, Kunal, et al.
Publicado: (2020)

Dose banding – Weighing up benefits, risks and therapeutic failure
por: Duffull, Stephen
Publicado: (2022)

Nanosilver: Weighing the Risks and Benefits
por: Seltenrich, Nate
Publicado: (2013)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Iohexol Plasma Clearance: Impact of Weighing the Syringe
por: Delanaye, Pierre, et al.
Publicado: (2021)

Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Farag, Youssef M.K.
Publicado: (2020)

Convalescent plasma to treat COVID-19: Its challenges in Iraq's situation
por: Hashim, H.T.
Publicado: (2020)

Challenges in the production of COVID-19 convalescent plasma- analysis of donor recruitment
por: Sekiya, Eliseo Joji, et al.
Publicado: (2021)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response)
por: De Santis, Gil C., et al.
Publicado: (2022)

COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors
por: Bansal, N., et al.
Publicado: (2021)

The emergency use authorization for COVID‐19 convalescent plasma reduced mortality
por: Paneth, Nigel, et al.
Publicado: (2023)

Combining pharmacological treatments in geriatric population: Weighing the balance
por: Bhad, R, et al.
Publicado: (2015)

Nomenclature and treatment of secondary urethral strictures following primary hypospadias repair: weighing up academic principles and clinical pragmatism
por: Vetterlein, Malte W., et al.
Publicado: (2020)

Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials
por: Dimosiari, Athina, et al.
Publicado: (2022)

In Reply — Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Joyner, Michael. J., et al.
Publicado: (2020)

Early and persistent viral clearance in COVID-19 patients treated with convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2021)

Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma
por: Vazquez, Sara E., et al.
Publicado: (2021)

Covid-19 convalescent plasma and SARS-CoV-2 viral variants
por: Joob, B., et al.
Publicado: (2021)

Convalescent plasma trial shows no benefit
por: Brown, Matthew
Publicado: (2020)

Antimicrobial stewardship programs and convalescent plasma for COVID-19: A new paradigm for preauthorization?
por: Stevens, Michael P., et al.
Publicado: (2020)

Whole blood derived covid convalescent plasma: An economical option among developing countries
por: Ravula, Ushasree, et al.
Publicado: (2021)

Whole blood derived covid convalescent plasma: A practical experience from India
por: Mandal, Abhijit, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_01ifcemvlqk8m703sh6o0lgi6a